Literature DB >> 31291512

Reforming the Orphan Drug Act for the 21st Century.

Ameet Sarpatwari1, Aaron S Kesselheim1.   

Abstract

Mesh:

Substances:

Year:  2019        PMID: 31291512     DOI: 10.1056/NEJMp1902943

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  11 in total

1.  Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy.

Authors:  Dhruv S Kazi; Brandon K Bellows; Suzanne J Baron; Changyu Shen; David J Cohen; John A Spertus; Robert W Yeh; Suzanne V Arnold; Brett W Sperry; Mathew S Maurer; Sanjiv J Shah
Journal:  Circulation       Date:  2020-02-12       Impact factor: 29.690

2.  The Evaluation of Orphan Drugs by the German Joint Federal Committee-An Eight-Year Review.

Authors:  Sandra Schulz; Anna Marie Passon; Matthias Perleth; Michael Kulig; Nina Paschke; Katja Matthias
Journal:  Dtsch Arztebl Int       Date:  2020-12-11       Impact factor: 5.594

3.  Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.

Authors:  George Goshua; Pranay Sinha; Jeanne E Hendrickson; Christopher Tormey; Pavan K Bendapudi; Alfred Ian Lee
Journal:  Blood       Date:  2021-02-18       Impact factor: 22.113

4.  Estimating the size of the United States market for new antibiotics with activity against carbapenem-resistant Enterobacteriaceae.

Authors:  Cornelius J Clancy; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2019-10-07       Impact factor: 5.191

5.  Rarely mentioned: how we arrived at the quantitative definition of a rare disease.

Authors:  Clyde Partin
Journal:  Proc (Bayl Univ Med Cent)       Date:  2022-03-28

6.  Spending For Orphan Indications Among Top-Selling Orphan Drugs Approved To Treat Common Diseases.

Authors:  Kao-Ping Chua; Lauren E Kimmel; Rena M Conti
Journal:  Health Aff (Millwood)       Date:  2021-03       Impact factor: 6.301

7.  Response by Kazi et al to Letter Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy".

Authors:  Dhruv S Kazi; Brandon K Bellows; John A Spertus; Suzanne J Baron; Changyu Shen; David J Cohen; Robert W Yeh; Suzanne V Arnold; Brett W Sperry; Mathew S Maurer; Sanjiv J Shah
Journal:  Circulation       Date:  2020-10-12       Impact factor: 39.918

8.  Effects of socio-economic factors on research over systemic sclerosis: an analysis based on long time series of bibliometric data.

Authors:  Wei Guo; Zeyu Zhou; Yinhe Liang; Chuanhui Xu; Lin Zeng; Zhiyong Dong; Rong Mu
Journal:  Orphanet J Rare Dis       Date:  2021-12-20       Impact factor: 4.123

Review 9.  The Price of Progress: Cost, Access, and Adoption of Novel Cardiovascular Drugs in Clinical Practice.

Authors:  Merilyn S Varghese; Chia-Liang Liu; Dhruv S Kazi
Journal:  Curr Cardiol Rep       Date:  2021-10-01       Impact factor: 2.931

10.  Therapeutic Value Assessments of Novel Medicines in the US and Europe, 2018-2019.

Authors:  Kerstin N Vokinger; Thomas J Hwang; Camille E G Glaus; Aaron S Kesselheim
Journal:  JAMA Netw Open       Date:  2022-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.